Inventaire - your friends and communities are your best library - Inventaire

Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring

author

Mel Ziman

Elin S Gray

published in: Frontiers in Oncology

date of publication: 2013-03-19

main subject: dabrafenib, metastatic melanoma

Cites articles 120

Date

Title

Authors

2013-01-01

Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV disease.
2012-11

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Igor Puzanov, Adil Daud, Georgina V. Long, Richard F. Kefford, Keith Flaherty, Jeffrey S Weber, Jeffrey A Sosman, Nageatte Ibrahim, Peter F Lebowitz, Omid Hamid, Lynn Schuchter, Jonathan Cebon, Ragini R Kudchadkar, Howard A Burris, Gerald Falchook, Alain P Algazi, Shonda Little, Daniele Ouellet, Kiran D Patel
2012-11-15

Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression

Markus H. Frank, Tapan Rai, Mel Ziman
2012-08-13

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

Pier Francesco Ferrucci, Paola Queirolo, Michele Maio, Mario Santinami, Licia Rivoltini, Diana Giannarelli, Paolo Antonio Ascierto, Ester Simeone
2012-09

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

Joseph Schlessinger, Edna Holman, Gerald Goh, Yong Kong, Michael Krauthammer, Antonella Bacchiocchi, Mario Sznol, Kenneth Kidd, Titus J Boggon
2012-07-20

A landscape of driver mutations in melanoma

Eric Lander, Gad Getz, Kristian Cibulskis, Wendy Winckler, Daniel Auclair, Gordon Saksena, Eran Hodis, Nicolas Stransky, Douglas Voet, Kristin Ardlie, Elizabeth Nickerson, Lynda Chin, Jean-Philippe Theurillat, Marcin Imielinski, Dirk Schadendorf, Jennifer Wargo, Donald Morton, John E. Ladbury, Gregory Kryukov, Katherine Stemke-Hale, Stefan T Arold, Stephan N. Wagner, Matthew Meyerson, Stacey Gabriel, Levi A Garraway, Andrey Sivachenko, Alex H Ramos
2012-08

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

Razelle Kurzrock, Keith Flaherty
2012-10-05

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

Richard Scolyer, Georgina V. Long, Pablo Fernandez-Peñas
2012-07-05

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

Nicolas Pécuchet, Olivier Mir
2012-06-25

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Jean-Jacques Grob, Piotr Rutkowski, Vanna Chiarion Sileni, Christian U Blank
2012-06-04

Improved survival with MEK inhibition in BRAF-mutated melanoma

Claus Garbe, Mohammed Milhem, Piotr Rutkowski, Jochen Utikal, Jürgen C Becker, Reinhard Dummer
2012-06-28

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Luis H Camacho, Kunle Odunsi, Henry C Pitot, Charles G. Drake, Patrick Hwu, Drew M Pardoll, Suzanne L. Topalian
2012-06-28

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Mario Sznol, Charles G. Drake, F Stephen Hodi, Tracee L. McMiller, Suzanne L. Topalian, Drew M Pardoll, Janis M Taube
2012-06-28

Tumor Immunotherapy Directed at PD-1

Antoni Ribas
2012-05-24

Melanoma genome sequencing reveals frequent PREX2 mutations

Eric Lander, Carrie Sougnez, Gad Getz, Kristian Cibulskis, Daniel Auclair, Wendy Winckler, Lauren Ambrogio, Gordon Saksena, Eran Hodis, Nicolas Stransky, Douglas Voet, Kristin Ardlie, Elizabeth Nickerson, Lynda Chin, Jennifer Baldwin, Dirk Schadendorf, Jennifer Wargo, Melissa Parkin, Petar Stojanov, Yotam Drier, Jordi Barretina Ginesta, Trevor J Pugh, Stephan N. Wagner, Antje Sucker, Matthew Meyerson, Stacey Gabriel, Levi A Garraway, Todd Golub
2012-05-01

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Georgina V. Long, Michael P. Brown, Richard F. Kefford, Razelle Kurzrock, Michael Millward, Peter F Lebowitz, Omid Hamid, Gerald Falchook, Daniele Ouellet, Jeffrey R Infante, Anna C Pavlick
2012-04-01

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors

Bartosz Chmielowski, Antoni Ribas, Georgina V. Long, Richard F. Kefford, Antonella Bacchiocchi, Gulietta M Pupo, Xiangju Kong, Jeffrey A Sosman, Hubing Shi, Richard C Koya, Gatien Moriceau
2012-05-08

Receptor tyrosine kinases in cancer escape from BRAF inhibitors
2012-01-16

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

Mari Mino-Kenudson, Keith Flaherty, Dora Dias-Santagata, Jeffrey A Engelman, Ryan B Corcoran, Jeffrey Settleman, Jennifer Wargo
2012-03-20

Expression of chemokine receptors on circulating tumor cells in patients with solid tumors

Ulrich Keilholz
2012-03-06

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

Hubing Shi, Richard Scolyer, Richard F. Kefford, Georgina V. Long, Antoni Ribas, Xiangju Kong, Jeffrey A Sosman, Richard C Koya, Gatien Moriceau, Thinle Chodon, Stanley F Nelson
2012-02-23

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Bartosz Chmielowski, Antoni Ribas, Igor Puzanov, Grant McArthur, Richard F. Kefford, Keith Flaherty
2012-02-20

RAF265 inhibits the growth of advanced human melanoma tumors

Ann Richmond, Kelli L. Boyd
2012-01-26

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Federica Di Nicolantonio, Alberto Bardelli, Chong Sun, René Bernards, Davide Zecchin
2012-01-26

Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level
2012-03-01

Sunitinib therapy for melanoma patients with KIT mutations

Boris C. Bastian
2012-01-01

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

Nathalie Dhomen, Caroline J Springer, Bartosz Chmielowski, Grant McArthur, Richard Marais, Gideon Bollag, Antoni Ribas, Gaston Habets, Keith Flaherty, Chao Zhang, Jorge Reis-Filho, Maryou B K Lambros
2012-02-13

Reviewing the somatic genetics of melanoma: from current to future analytical approaches
2012

Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma

Russell Berman
2012-02-01

Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma

Donald Morton, Nicola Mozzillo
2012-09-15

Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells

Mel Ziman, James B Freeman, Elin S Gray
2012-12-06

Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.

Paul Lorigan, Caroline Dive, Andrew Hughes, Raffaele Califano

Article - wd:Q38091649

Welcome to Inventaire

the library of your friends and communities

you are offline